Related Experiment Video
Updated: Jan 15, 2026

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
Safety Profile of Meloxicam: Analysis of Adverse Event Reports in the Czech Republic
Jana Mlíchová1, Vojtěch Mészáros1, Ondřej Šimandl1
1Department of Pharmacology, Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Introduction:
Meloxicam is a preferential cyclooxygenase-2 inhibitor widely prescribed for rheumatic diseases. Given its long clinical use, further assessment of its safety profile remains relevant.
Aim Of Study:
This study aimed to evaluate the safety profile of meloxicam in the Czech Republic using national pharmacovigilance data, and to compare reported adverse events (AEs) with findings from the WHO VigiAccess database.
Methods:
We analyzed all meloxicam-related AEs reported to the State Institute for Drug Control (SÚKL) between January 2015 and December 2020, as well as related data extracted from the World Health Organization's pharmacovigilance VigiAccess database. AEs were classified according to MedDRA terminology. National drug utilization data were obtained from SÚKL to provide an estimate of meloxicam exposure, expressed in defined daily doses (DDD).
Results:
Over six years, 24 AE reports were identified in the Czech Republic (population 10.7 million). During the same period, meloxicam consumption reached 71,512,140 DDD, corresponding to 4.64 DDD/1000 inhabitants/day. The most frequently reported AEs were hypersensitivity reactions (10 cases), followed by gastrointestinal events (4 cases), nervous system disorders (4 cases), and isolated cardiovascular toxicity (1 case of heart failure).
Conclusion:
In the context of national exposure, only a limited number of meloxicam-related AEs were reported.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Therapeutic Drug Monitoring: Overview and Classification
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Bioequivalence studies: Biowaivers

